Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan in Neoadjuvant Early-Stage TNBC
NCT07007780Phase 2Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in triple-negative breast cancer (TNBC), sponsored by Xijing Hospital. Primary endpoint: Pathological Complete Response Rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07007780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007780.